Join us for the 10th annual Gretschen Amphlet Memorial Lecture.
Pioneering the Treatments of Tomorrow
This year we are celebrating two major milestones, Parkinson’s UK will mark its 50th anniversary in the same year as the 10th Gretchen Amphlet Memorial Lecture. So, we’re asking what do we have to celebrate?
On the surface it may seem there have been no major advances in the treatments available for Parkinson’s in the past decade. No current treatment can slow or stop its progression. But, in many ways, this is not reflective of the momentum that is building in Parkinson’s research. In 2019, we are at the brink - the science ready, we have the expertise, and new treatments are within our grasp.
Join us to hear Professor Roger Barker, University of Cambridge and Dr Beckie Port, Parkinson’s UK, discuss the huge scientific progress that has happened in the last 10 years. You will hear about the challenges that have been overcome and the discoveries that are on the verge of delivering new and better treatments. We invite you to come and celebrate with us and help turn hopes into reality.
You'll hear from Dr Beckie Port, Research Communications Manager at Parkinson's UK, who will discuss the landmarks in Parkinson's research, followed by Professor Roger Barker, Professor of Clinical Neuroscience at the University of Cambridge, who will be discussing 10 years of breakthroughs. You will also have the chance to put your questions to our panel.
After the lecture, from 8pm, we invite the audience to join us in the Auditorium Foyer for a post-event reception with light refreshments, to celebrate the tenth annual Gretschen Amphlet Memorial Lecture.
Places are free but must be booked in advance.
Roger Barker is the Professor of Clinical Neuroscience at the University of Cambridge and Consultant Neurologist at the Addenbrooke’s Hospital Cambridge. He is a PI in the MRC-Wellcome Trust Stem Cell Institute in Cambridge and the new Director of the MRC funded UKRMP Stem and Engineered cell hub.
His research seeks to better define the clinical heterogeneity of two common neurodegenerative disorders of the CNS- namely Parkinson’s (PD) and Huntington’s disease (HD). This has helped him define the best way by which to take new therapies into the clinic. In this respect he has been heavily involved in gene and cell based trials for patients with these conditions and currently co-ordinates an EU funded transplant programme using human fetal tissue for patients with PD, following on from an earlier MRC funded trial using similar tissue in HD. He is part of a global initiative (GFORCE-PD) that is seeking to take stem cells to trial in PD.
Beckie Port is the Research Communications Manager at Parkinson’s UK and the current editor of our research magazine, Progress.
She joined the charity 5 years ago following the completion of a PhD on the relationship between the Epstein-Barr virus and cancer stem cell production. Prior to joining Parkinson’s UK, she has also worked in drug discovery for the global pharmaceutical company Merck Sharp and Dohme, where her research focused on the pre-clinical testing of potential pharmaceuticals for the treatment of cognitive problems in schizophrenia.